Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely

This article was originally published in The Pink Sheet Daily

Executive Summary

With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.

Advertisement

Related Content

AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
Lilly Poised To Lead In Alzheimer’s, But Success Depends On Solanezumab
Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa
Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s
Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s
A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway
Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
Beyond Bapi: Alzheimer’s Pipeline Runs Deep
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
Lilly's Semagacestat Is Latest Alzheimer's Drug To Fail; Is Class At Risk?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel